The EGFR as a target for anticancer therapy - Focus on cetuximab

European Journal of Cancer

Volumn 37, Issue SUPPL. 4, 2001, Pages 16-22

  Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antibodies; Antineoplastic agents; Chimeric proteins; Cisplatin; Colorectal neoplasms; Drug; Head and neck neoplasms; Monoclonal; Receptor, Epidermal growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEMCITABINE; M 225; MONOCLONAL ANTIBODY; PACLITAXEL; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG ELIMINATION; HEAD AND NECK CARCINOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOTHERAPY; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 0034779291     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)00233-7     Document Type: Article

References (45)

1. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
2. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results
3. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors
4. Epidermal growth factor-related peptides and their receptors in human malignancies
5. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
6. Activated epidermal growth factor receptor: Studies in head and neck tumors and tumor cell lines after exposure to ligand and receptor tyrosine-kinase inhibitors
7. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation
8. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2
9. Involvement of p27Kip1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody
10. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27Kip1 and induces G1 arrest in prostatic cancer cell line DU145
11. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
12. Jeremiah Metzger Lecture. Targeted cancer therapy
13. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo
14. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
15. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
16. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion
17. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands
18. Blockade of EGF-R signaling with anti-EGFR monoclonal antibody (Mab) C225 inhibits matrix metalloproteinase-9 (MMP-9) expression and invasion of human transitional cell carcinoma (TCC) in vitro and in vivo
19. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance
20. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin
21. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells
22. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer do not involve the c-jun N-terminal kinase activity
23. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth
24. Altered cell cycle distribution and cyclin-CDK protein expression in A431 epidermoid carcinoma cells treated with doxorubicin and a chimeric monoclonal antibody to the epidermal growth factor receptor
25. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
26. Paclitaxel enhances the effect of treatment of metastatic human transitional cell carcinoma with the anti-epidermal growth factor receptor monoclonal antibody C225
27. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice
28. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
29. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
30. Anti-EGF receptor monoclonal antibody IMC-C225 combined with docetaxel inhibits growth of renal cell carcinoma tumors in a nude mouse model
31. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation
32. In vivo enhancement of tumor radioresponse by C225 anti-epidermal growth factor receptor antibody
33. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
34. Safety profile of the monoclonal antibody (MOAB) IMC-C225, an anti-epidermal growth factor receptor (EGFR) used in the treatment of EGFR-positive tumors
35. Low immunogenicity of a chimeric monoclonal antibody (MOAB), IMC-C225, used to treat epidermal growth factor receptor-positive tumors
36. A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC)
37. Monoclonal antibody (MOAB) IMC-C225, an anti-epidermal growth factor receptor (EGFR), for patients (PTS) with EGFR-positive tumors refractory to or in relapse from previous therapeutic regimens
38. Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOC) in androgen-independent (AI) prostate cancer (PC): Results of a phase Ib/IIa study
39. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival
40. Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies
41. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial
42. Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer
43. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
44. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003
45. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma